39 recruiting, 34 completed, 16 not yet recruiting, 14 terminated. 125 Phase 1, 49 Phase 2.
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis | Phase 1 | Not yet recruiting | AbelZeta Inc. | 12 | 2027-03-01 | 2026-10-13 |
| An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 36 | 2027-01-01 | 2026-11-12 |
| Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases HN2302 Injection - Autoimmune Disease, Systemic Lupus Erythematosus | Phase 1 | Not yet recruiting | Shenzhen MagicRNA Biotechnology Co., Ltd | 12 | 2026-12-31 | 2026-08-12 |
| Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases anti-CD19 CAR-T cells - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 1 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 6 | 2026-12-01 | 2026-09-02 |
| A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases QLS2416 Injection - Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA) | Phase 1 | Not yet recruiting | Shanghai Qilu Pharmaceutical Research and Development Center LTD | 76 | 2026-12-01 | 2026-10-30 |
| A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Not yet recruiting | Pfizer | 54 | 2026-11-19 | 2026-10-01 |
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 60 | 2026-10-30 | 2026-10-14 |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease LMY-922 - Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE) | Phase 1 | Not yet recruiting | Luminary Therapeutics | 94 | 2026-10-01 | 2026-07-28 |
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| A Study of ATG-201 in Adult Participants With Autoimmune Diseases ATG-201 - Systemic Lupus Erythematosus, Systemic Sclerosis (SSc) | Phase 1 | Recruiting | Antengene Biologics Limited | 149 | 2026-09-26 | 2026-10-28 |
| A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body HBM7020 - Rheumatoid Arthritis, Systemic Lupus Erythematosus | Phase 1 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 63 | 2026-09-24 | 2026-11-05 |
| A Study to Test CRT-402 in Refractory Autoimmune Disease CRT-402 - Autoimmune Diseases, Systemic Lupus Erythematosus | Phase 1 / Phase 2 | Recruiting | Myeloid Therapeutics | 34 | 2026-08-26 | 2026-10-22 |
| Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases Allogeneic CD19/BCMA-targeted CAR-γδT cell injection, Cyclophosphamide, Fludarabine - Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 9 | 2026-07-01 | 2026-06-09 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| US Zamto-cel Autoimmune Diseases zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine - Lupus Nephritis, Systemic Lupus Erythematosus | Phase 1 | Recruiting | Miltenyi Biomedicine GmbH | 48 | 2026-07-01 | 2026-06-11 |
| Controlling Hyperactive Immunity With Long-lived Lymphocytes QEL-005 - Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA) | Phase 1 / Phase 2 | Recruiting | Quell Therapeutics Limited | 16 | 2026-04-10 | 2026-10-19 |
| Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Systemic Sclerosis HS_SW01 cells injection - Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Huishan Biotechnology Co., Ltd. | 21 | 2026-04-10 | 2026-04-21 |
| Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. umbilical cord blood CD19-BCMA CAR-T cells infusion - Refractory Lupus Nephritis, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 45 | 2026-03-18 | 2026-03-03 |
| A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases CLBR001 + SWI019 - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Withdrawn | Calibr, a division of Scripps Research | 2026-03-01 | 2026-03-05 |
Showing 20 of 125. Sign in to see all of them.
Scleroderma, Diffuse (48) · Lupus Erythematosus, Systemic (47) · Myositis (32) · Autoimmune Diseases (24) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (21) · Arthritis, Rheumatoid (18) · Lupus Nephritis (18) · Sjogren's Syndrome (15) · Dermatomyositis (14) · Antiphospholipid Syndrome (6) · Multiple Sclerosis (6) · Polymyositis (6) · Myasthenia Gravis (4) · Arthritis, Juvenile (3)
Skin and Connective Tissue Diseases (125) · Skin Diseases (124) · Connective Tissue Diseases (123) · Immune System Diseases (61) · Musculoskeletal Diseases (46) · Nervous System Diseases (44) · Neuromuscular Diseases (43) · Muscular Diseases (40) · Autoimmune Diseases (39) · Joint Diseases (31) · Rheumatic Diseases (31) · Arthritis (30) · Cardiovascular Diseases (25) · Vascular Diseases (24) · Skin Diseases, Vascular (22)
Cyclophosphamide (15) · fludarabine (14) · fludarabine phosphate (3) · Alemtuzumab (2) · Imatinib Mesylate (2) · Immunotherapy, Adoptive (2) · Leukapheresis (2) · Mycophenolic Acid (2) · Stem Cell Transplantation (2) · Tacrolimus (2) · Whole-Body Irradiation (2) · tocilizumab (2) · Abatacept (1) · Bendamustine Hydrochloride (1) · Biopsy (1)
Beijing GoBroad Hospital (5) · Boston University (3) · Bristol-Myers Squibb (3) · China Immunotech (Beijing) Biotechnology Co., Ltd. (3) · Amgen (2) · Assistance Publique - Hôpitaux de Paris (2) · Chongqing Precision Biotech Co., Ltd (2) · Fate Therapeutics (2) · Fred Hutchinson Cancer Center (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Jiangsu Renocell Biotech Company (2) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (2) · MedImmune LLC (2) · Miltenyi Biomedicine GmbH (2) · Peking University Third Hospital (2)
United States (57) · China (30) · France (10) · Germany (10) · Spain (9) · Australia (7) · Canada (6) · United Kingdom (6) · Belgium (4) · Israel (4) · Poland (4) · Italy (3) · Netherlands (3) · Argentina (2) · Norway (2)
Robert Lafyatis, MD (4) · Adam Raff, MD, PhD (1) · Andrei Hancharou, Dr (1) · Ann Woolfrey (1) · Ann-Christin Pecher (1) · Anna-Maria Hoffmann-Vold, PhD (1) · Antonia Valenzuela, MD, MS (1) · Arnon Aharon, MD (1)
PMID 19180499, PMID 19950289, PMID 21769849, PMID 22542159, PMID 23597147, PMID 24559157, PMID 26071192, PMID 26098215, PMID 27267753, PMID 28387950, PMID 28724445, PMID 29121645, PMID 30127049, PMID 30277862, PMID 34664183, PMID 35470301, PMID 35943798, PMID 36688692, PMID 36928395, PMID 36997069, PMID 38206544, PMID 38501358, PMID 40013233, PMID 41501497, PMID 42177178
2018 (2), 2015 (1), 2023 (1), 2025 (1), K23AR002187 (1), R01AI041721 (1), R21AR065089 (1), UM1AI109565 (1), UM1CA186688 (1)